Amphotericin B | Fungizone | CAS#1397-89-3 | Ergosterol Binder

MedKoo Cat#: 540017 | Name: Amphotericin B

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amphotericin B binds ergosterol and induces membrane pore formations, increasing ROS and suppressing fungal growth. It also increases expression of IL-1-beta, TNF-alpha, BDNF and GDNF and protects against prion-induced neurodegeneration.

Chemical Structure

Amphotericin B

CAS#1397-89-3 (Amphotericin B)

Theoretical Analysis

MedKoo Cat#: 540017

Name: Amphotericin B

CAS#: 1397-89-3 (Amphotericin B)

Chemical Formula: C47H73NO17

Exact Mass: 923.4878

Molecular Weight: 924.09

Elemental Analysis: C, 61.09; H, 7.96; N, 1.52; O, 29.43

Price and Availability

Size	Price	Availability	Quantity
1g	USD 350.00	2 Weeks
5g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1405-32-9 (Amphotericin A) 1397-89-3 (Amphotericin B) 36148-89-7 (Amphotericin B methyl ester)

Synonym

Amphotericin B; Fungizone

IUPAC/Chemical Name

(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid

InChi Key

APKFDSVGJQXUKY-INPOYWNPSA-N

InChi Code

InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1

SMILES Code

O=C([C@@H]([C@](O1)([H])C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)O3)[C@@H](O)C[C@@]1(O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC3=O)O

Appearance

Yellow to orange solid powder.

Purity

>90% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 924.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Azanza JR, Sádada B, Reis J. Liposomal formulations of amphotericin B: differences according to the scientific evidence. Rev Esp Quimioter. 2015 Dec;28(6):275-81. Review. PubMed PMID: 26621170. 2: Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4. Review. PubMed PMID: 23729001. 3: Houdek MT, Greenwood-Quaintance KE, Morrey ME, Patel R, Hanssen AD. Elution of High Dose Amphotericin B Deoxycholate From Polymethylmethacrylate. J Arthroplasty. 2015 Dec;30(12):2308-10. doi: 10.1016/j.arth.2015.06.002. Epub 2015 Jun 11. PubMed PMID: 26162513. 4: Belhachemi MH, Boucherit K, Boucherit-Otmani Z, Belmir S, Benbekhti Z. Effects of ascorbic acid and α-tocopherol on the therapeutic index of amphotericin B. J Mycol Med. 2014 Dec;24(4):e137-42. doi: 10.1016/j.mycmed.2014.04.003. Epub 2014 Oct 16. PubMed PMID: 25442914. 5: Undre NA, Stevenson P, Wilbraham D. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects. Int J Clin Pharmacol Ther. 2014 Mar;52(3):237-44. doi: 10.5414/CP202015. PubMed PMID: 24472403. 6: Souza AC, Nascimento AL, de Vasconcelos NM, Jerônimo MS, Siqueira IM, R-Santos L, Cintra DO, Fuscaldi LL, Pires Júnior OR, Titze-de-Almeida R, Borin MF, Báo SN, Martins OP, Cardoso VN, Fernandes SO, Mortari MR, Tedesco AC, Amaral AC, Felipe MS, Bocca AL. Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles. Eur J Med Chem. 2015 May 5;95:267-76. doi: 10.1016/j.ejmech.2015.03.022. Epub 2015 Mar 14. PubMed PMID: 25827397. 7: Adler-Moore JP, Gangneux JP, Pappas PG. Comparison between liposomal formulations of amphotericin B. Med Mycol. 2016 Mar;54(3):223-31. doi: 10.1093/mmy/myv111. Epub 2016 Jan 14. Review. PubMed PMID: 26768369. 8: Janout V, Schell WA, Thévenin D, Yu Y, Perfect JR, Regen SL. Taming Amphotericin B. Bioconjug Chem. 2015 Oct 21;26(10):2021-4. doi: 10.1021/acs.bioconjchem.5b00463. Epub 2015 Sep 10. PubMed PMID: 26340430. 9: Al-Saigh R, Siopi M, Siafakas N, Velegraki A, Zerva L, Meletiadis J. Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013 Aug;57(8):3713-8. doi: 10.1128/AAC.02484-12. Epub 2013 May 28. PubMed PMID: 23716054; PubMed Central PMCID: PMC3719712. 10: Tang X, Zhu H, Sun L, Hou W, Cai S, Zhang R, Liu F. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo. Int J Nanomedicine. 2014 Nov 24;9:5403-13. doi: 10.2147/IJN.S71623. eCollection 2014. PubMed PMID: 25473279; PubMed Central PMCID: PMC4247144. 11: Mishra J, Dey A, Singh N, Somvanshi R, Singh S. Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model. Indian J Med Res. 2013 Apr;137(4):767-76. PubMed PMID: 23703346; PubMed Central PMCID: PMC3724259. 12: Berman J. Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg. 2015 Mar;92(3):471-3. doi: 10.4269/ajtmh.14-0743. Epub 2014 Dec 15. PubMed PMID: 25510726; PubMed Central PMCID: PMC4350529. 13: Bhatia S, Kumar V, Sharma K, Nagpal K, Bera T. Significance of algal polymer in designing amphotericin B nanoparticles. ScientificWorldJournal. 2014;2014:564573. doi: 10.1155/2014/564573. Epub 2014 Nov 12. PubMed PMID: 25478596; PubMed Central PMCID: PMC4244925. 14: Ickowicz DE, Farber S, Sionov E, Kagan S, Hoffman A, Polacheck I, Domb AJ. Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide. Biomacromolecules. 2014 Jun 9;15(6):2079-89. doi: 10.1021/bm5002125. Epub 2014 May 16. PubMed PMID: 24779556. 15: Al-Quadeib BT, Radwan MA, Siller L, Mutch E, Horrocks B, Wright M, Alshaer A. Therapeutic monitoring of amphotericin B in Saudi ICU patients using UPLC MS/MS assay. Biomed Chromatogr. 2014 Dec;28(12):1652-9. doi: 10.1002/bmc.3198. Epub 2014 Apr 14. PubMed PMID: 24733605. 16: Mudavath SL, Talat M, Rai M, Srivastava ON, Sundar S. Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies. Drug Des Devel Ther. 2014 Sep 4;8:1235-47. doi: 10.2147/DDDT.S63994. eCollection 2014. PubMed PMID: 25214767; PubMed Central PMCID: PMC4159315. 17: Kaur L, Jain SK, Manhas RK, Sharma D. Nanoethosomal formulation for skin targeting of amphotericin B: an in vitro and in vivo assessment. J Liposome Res. 2015;25(4):294-307. doi: 10.3109/08982104.2014.995670. Epub 2014 Dec 30. PubMed PMID: 25547800. 18: Asthana S, Gupta PK, Jaiswal AK, Dube A, Chourasia MK. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Nanomedicine (Lond). 2015;10(7):1093-109. doi: 10.2217/nnm.14.182. PubMed PMID: 25929567. 19: Casa DM, Carraro TC, de Camargo LE, Dalmolin LF, Khalil NM, Mainardes RM. Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In Vitro Antifungal Activity. J Nanosci Nanotechnol. 2015 Jan;15(1):848-54. PubMed PMID: 26328449. 20: Zia Q, Khan AA, Swaleha Z, Owais M. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Int J Nanomedicine. 2015 Mar 5;10:1769-90. doi: 10.2147/IJN.S63155. eCollection 2015. PubMed PMID: 25784804; PubMed Central PMCID: PMC4356689.